Adagene Croissance future

Future contrôle des critères 2/6

Les bénéfices de Adagene devraient diminuer de 10.5% par an tandis que son chiffre d'affaires annuel devrait croître de 58.3% par an. Le BPA devrait croître de de 9.2% par an. Le rendement des capitaux propres devrait être -206% dans 3 ans.

Informations clés

-10.5%

Taux de croissance des bénéfices

9.2%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	58.3%
Rendement futur des capitaux propres	-206.0%
Couverture par les analystes	Low
Dernière mise à jour	15 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Oct 10

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Oct 05

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Aug 30

Micro-cap Adagene surges after hours on $10M share buyback

Jun 29

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:ADAG - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	13	-104	-70	-97	3
12/31/2025	13	-80	-53	-69	3
12/31/2024	12	-43	-29	-47	3
6/30/2024	1	-32	-28	-28	N/A
3/31/2024	9	-25	-29	-28	N/A
12/31/2023	18	-19	-29	-28	N/A
9/30/2023	20	-28	N/A	N/A	N/A
6/30/2023	23	-36	N/A	N/A	N/A
3/31/2023	16	-58	N/A	N/A	N/A
12/31/2022	9	-80	-49	-49	N/A
9/30/2022	11	-82	N/A	N/A	N/A
6/30/2022	13	-84	N/A	N/A	N/A
3/31/2022	11	-78	N/A	N/A	N/A
12/31/2021	10	-73	-46	-43	N/A
9/30/2021	6	-68	N/A	N/A	N/A
6/30/2021	2	-62	N/A	N/A	N/A
3/31/2021	1	-52	N/A	N/A	N/A
12/31/2020	1	-43	-29	-29	N/A
9/30/2020	1	-34	-27	-26	N/A
6/30/2020	1	-28	-21	-21	N/A
3/31/2020	1	-22	-20	-20	N/A
12/31/2019	0	-17	-18	-18	N/A
12/31/2018	2	-14	-15	-14	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ADAG devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ADAG devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ADAG devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ADAG ( 58.3% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ADAG ( 58.3% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: ADAG devrait être non rentable dans 3 ans.

Adagene Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 32% to US$9.16

Price target decreased by 9.4% to US$12.53

Price target increased to US$13.82

Price target decreased to US$10.78

Price target decreased to US$12.71

Consensus forecasts updated

Recent updates

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.83 loss per share (vs US$1.85 loss in FY 2022)

Adagene Inc. Announces Board Changes

New minor risk - Financial data availability

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody

New major risk - Share price stability

Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium

Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.16

Full year 2022 earnings released: US$1.85 loss per share (vs US$1.83 loss in FY 2021)

Price target decreased by 9.4% to US$12.53

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial

Price target increased to US$13.82

Price target decreased to US$10.78

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

Price target decreased to US$12.71

High number of new and inexperienced directors

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Consensus forecasts updated

Adagene Inc. Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Price target increased to US$27.92

First half 2022 earnings released: US$1.09 loss per share (vs US$1.02 loss in 1H 2021)

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Adagene Inc. (NasdaqGM:ADAG) announces an Equity Buyback for $10 million worth of its shares.

Micro-cap Adagene surges after hours on $10M share buyback

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels

High number of new and inexperienced directors

Adagene Inc. Presents Data Demonstrating First and Best-In-Class Potential for Differentiated Preclinical Antibody Candidates At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$25.69

Adagene Inc. Announces Board and Management Changes

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

Adagene Inc. Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1B/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

Director Yu Miao has left the company

Adagene Inc. Announces Clinical Data from its ADG106 NEObodyTM Program

Adagene Inc. Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126 for the Treatment of Various Advanced Solid Tumors

Adagene Inc. has completed an IPO in the amount of $139.726 million.

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance